The TEAD inhibitor race got very crowded, very fast.

Orion Pharma, the Finnish big pharma better known for Parkinson’s drugs and inhaled asthma therapies, has quietly positioned itself as one of the most advanced players going after the Hippo/YAP pathway in oncology.

On April 23, they initiated the TEADCO Phase 1b/2 basket trial for ODM-212, their oral pan-TEAD inhibitor. The trial enrolls across three cohorts: mesothelioma, KRAS G12C-mutant NSCLC, and pancreatic cancer. All three in combination with standard of care.

That’s their second active clinical trial for this asset. The first, called TEADES, is the Phase 2 monotherapy study in malignant pleural mesothelioma and epithelioid hemangioendothelioma that started dosing back in December 2025. ODM-212 also picked up FDA Orphan Drug Designation in mesothelioma on April 20. Four days later, TEADCO opens.

Two trials, one orphan designation, three tumor types. All in four months.

So why is everyone suddenly interested in TEAD?

The Hippo pathway is one of the last major cancer signaling pathways without an approved drug. TEAD transcription factors sit downstream of YAP/TAZ and drive tumor proliferation in a bunch of cancers where nothing else has worked, particularly mesothelioma (where NF2/Hippo loss is the dominant driver) and KRAS-driven lung and pancreatic tumors (where TEAD reactivation contributes to resistance).

If you can drug TEAD, you unlock a set of tumors that have resisted every other target.

And here’s where it gets interesting. Just this morning, we covered Amphista Therapeutics presenting AACR 2026 preclinical data on a TEAD molecular glue degrader. That’s a fundamentally different approach. Orion inhibits TEAD. Amphista destroys it.

Other players in the mix: BridGene Biosciences raised $28 million in a Series B+ in January 2026 to advance BGC-515, a covalent TEAD inhibitor, into solid tumor trials. Vivace Therapeutics (VT3989), Ikena Oncology (before their merger), and several Chinese biotechs are also pushing TEAD inhibitor candidates through early clinical development.

Orion is ahead of most of them.

They’re running combination studies while competitors are still in monotherapy dose escalation. The KRAS G12C combination cohort is particularly interesting because it sets up ODM-212 as a potential resistance-busting add-on to sotorasib or adagrasib, both of which lose efficacy as TEAD reactivates.

There’s a second story under the headline though. Orion is primarily known as a commercial-stage specialty pharma with FDA-approved androgen synthesis inhibitor ODM-208 for prostate cancer also in Phase 2. TEAD is their swing-for-the-fences oncology play. If ODM-212 hits in mesothelioma, Orion becomes a rare pharma name with a differentiated first-in-class oncology asset. If TEADCO shows combination activity in KRAS G12C NSCLC, it’s a billion-dollar drug.

And if Amphista’s degrader is still better? The pathway is the winner and Orion just ends up with one of several TEAD drugs in clinic.

Watch for TEADES mesothelioma readouts first. Those will tell the whole story about whether TEAD inhibition as a class works in humans.